Abstract
Purpose
The Glasgow Prognostic Score (GPS) and modified Glasgow Prognostic Score (mGPS) are shown to be reliable prognostic indexes in patients with operable and inoperable non-small cell lung cancer (NSCLC). Considering the difference between the two indexes lies in whether hypoalbuminemia without an elevated C-reactive protein (CRP) is associated with worse survival, this study aims to evaluate the prognostic performance of hypoalbuminemia in patients without an elevated CRP and to compare the prognostic value of GPS and mGPS in patients with operable and inoperable NSCLC.
Methods
The data of 2988 patients were retrospectively collected from the Shanghai Health Information Network. Univariate and multivariate Cox regression was performed to investigate the prognostic effect of albumin, CRP, GPS and mGPS. Restricted cubic spline was also performed to evaluate the relationship between albumin and hazard ratio. Kaplan–Meier survival curves were estimated and compared using the log-rank test. Additional discriminative ability of GPS and of mGPS was evaluated using the area under the curve and Harrell’s concordance index.
Results
Hypoalbuminemia was associated with worse survival in both operable and inoperable patients without an elevated CRP. The Kaplan–Meier survival curve of hypoalbuminemic patients without an elevated CRP was more close to the curve of patients with an elevated CRP and a normal albumin than to the curve of patients with neither of these abnormalities. Multivariate analysis, AUC and C-index all indicated that GPS had a higher prognostic value than mGPS.
Conclusions
Hypoalbuminemia was associated with worse survival in patients with or without an elevated CRP. GPS was superior to mGPS in predicting survival in operable and inoperable NSCLC patients.
Similar content being viewed by others
References
Alifano M, Falcoz PE, Seegers V, Roche N, Schussler O, Younes M, Antonacci F, Forgez P, Dechartres A, Massard G, Damotte D, Régnard J (2011) Preresection serum C-reactive protein measurement and survival among patients with resectable non-small cell lung cancer. J Thorac Cardiovasc Surg 142(5):1161–1167
Coussens LM, Werb Z (2002) Inflammation and cancer. Nature 420(6917):860–867. doi:10.1038/nature01322
Crumley AB, Stuart RC, McKernan M, McMillan DC (2010) Is hypoalbuminemia an independent prognostic factor in patients with gastric cancer? World J Surg 34(10):2393–2398. doi:10.1007/s00268-010-0641-y
Dajczman E, Kasymjanova G, Kreisman H, Swinton N, Pepe C, Small D (2008) Should patient-rated performance status affect treatment decisions in advanced lung cancer? J Thorac Oncol 3(10):1133–1136. doi:10.1097/JTO.0b013e318186a272
DeLong ER, DeLong DM, Clarke-Pearson DL (1988) Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 44(3):837–845
Ebbert JO, Yang P, Vachon CM, Vierkant RA, Cerhan JR, Folsom AR, Sellers TA (2003) Lung cancer risk reduction after smoking cessation: observations from a prospective cohort of women. J Clin Oncol 21(5):921–926
Espinosa E, Feliu J, Zamora P, Gonzalez BM, Sanchez JJ, Ordon EA, Espinosa J (1995) Serum albumin and other prognostic factors related to response and survival in patients with advanced non-small cell lung cancer. Lung Cancer 12(1–2):67–76
Fan H, Shao ZY, Xiao YY, Xie ZH, Chen W, Xie H, Qin GY, Zhao NQ (2015) Incidence and survival of non-small cell lung cancer in Shanghai: a population-based cohort study. BMJ Open 5:e009419. doi:10.1136/bmjopen-2015-009419
Fearon KC, Barber MD, Falconer JS, McMillan DC, Ross JA, Preston T (1999) Pancreatic cancer as a model: inflammatory mediators, acute-phase response, and cancer cachexia. World J Surg 23(6):584–588
Forrest LM, McMillan DC, McArdle CS, Angerson WJ, Dunlop DJ (2003) Evaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer. Br J Cancer 89(6):1028–1030. doi:10.1038/sj.bjc.6601242
Forrest LM, McMillan DC, McArdle CS, Angerson WJ, Dunlop DJ (2004) Comparison of an inflammation-based prognostic score (GPS) with performance status (ECOG) in patients receiving platinum-based chemotherapy for inoperable non-small-cell lung cancer. Br J Cancer 90(9):1704–1706. doi:10.1038/sj.bjc.6601789
Forrest LM, McMillan DC, McArdle CS, Angerson WJ, Dagg K, Scott HR (2005) A prospective longitudinal study of performance status, an inflammation-based score (GPS) and survival in patients with inoperable non-small-cell lung cancer. Br J Cancer 92(10):1834–1836. doi:10.1038/sj.bjc.6602591
Gagnon B, Abrahamowicz M, Xiao Y, Beauchamp ME, MacDonald N, Kasymjanova G, Kreisman H, Small D (2010) Flexible modeling improves assessment of prognostic value of C-reactive protein in advanced non-small cell lung cancer. Br J Cancer 102(7):1113–1122. doi:10.1038/sj.bjc.6605603
Gioulbasanis I, Pallis A, Vlachostergios PJ, Xyrafas A, Giannousi Z, Perdikouri IE, Makridou M, Kakalou D, Georgoulias V (2012) The Glasgow Prognostic Score (GPS) predicts toxicity and efficacy in platinum-based treated patients with metastatic lung cancer. Lung Cancer 77(2):383–388. doi:10.1016/j.lungcan.2012.04.008
Goldstraw P, Crowley J, Chansky K, Giroux DJ, Groome PA, Rami-Porta R, Postmus PE, Rusch V, Sobin L (2007) The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol 2(8):706–714. doi:10.1097/JTO.0b013e31812f3c1a
Harrell FJ, Lee KL, Mark DB (1996) Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 15(4):361–387. doi:10.1002/(SICI)1097-0258(19960229)15
Hastie T, Tibshirani R (1990) Generalized additive models. Chapman and Hall/CRC, London
Jiang AG, Chen HL, Lu HY (2015) The relationship between Glasgow Prognostic Score and serum tumor markers in patients with advanced non-small cell lung cancer. BMC Cancer 15:386. doi:10.1186/s12885-015-1403-x
Jin Y, Zhao L, Peng F (2013) Prognostic impact of serum albumin levels on the recurrence of stage I non-small cell lung cancer. Clinics (Sao Paulo) 68(5):686–693. doi:10.6061/clinics/2013(05)17
Kang L, Chen W, Petrick NA, Gallas BD (2015) Comparing two correlated C indices with right-censored survival outcome: a one-shot nonparametric approach. Stat Med 34(4):685–703. doi:10.1002/sim.6370
Kinoshita A, Onoda H, Imai N, Iwaku A, Oishi M, Tanaka K, Fushiya N, Koike K, Nishino H, Matsushima M (2015) The C-reactive protein/albumin ratio, a novel inflammation-based prognostic score, predicts outcomes in patients with hepatocellular carcinoma. Ann Surg Oncol 22(3):803–810. doi:10.1245/s10434-014-4048-0
Kishi T, Matsuo Y, Ueki N, Iizuka Y, Nakamura A, Sakanaka K, Mizowaki T, Hiraoka M (2015) Pretreatment Modified Glasgow Prognostic Score predicts clinical outcomes after stereotactic body radiation therapy for early-stage non-small cell lung cancer. Int J Radiat Oncol Biol Phys 92(3):619–626. doi:10.1016/j.ijrobp.2015.02.018
Koch A, Fohlin H, Sorenson S (2009) Prognostic significance of C-reactive protein and smoking in patients with advanced non-small cell lung cancer treated with first-line palliative chemotherapy. J Thorac Oncol 4(3):326–332. doi:10.1097/JTO.0b013e31819578c8
Leung EY, Scott HR, McMillan DC (2012) Clinical utility of the pretreatment glasgow prognostic score in patients with advanced inoperable non-small cell lung cancer. J Thorac Oncol 7(4):655–662. doi:10.1097/JTO.0b013e318244ffe1
Mantovani A (2009) Cancer: inflaming metastasis. Nature 457(7225):36–37. doi:10.1038/457036b
McMillan DC (2008) An inflammation-based prognostic score and its role in the nutrition-based management of patients with cancer. Proc Nutr Soc 67(3):257–262. doi:10.1017/S0029665108007131
McMillan DC (2009) Systemic inflammation, nutritional status and survival in patients with cancer. Curr Opin Clin Nutr Metab Care 12(3):223–226. doi:10.1097/MCO.0b013e32832a7902
McMillan DC, Scott HR, Watson WS, Preston T, Milroy R, McArdle CS (1998) Longitudinal study of body cell mass depletion and the inflammatory response in cancer patients. Nutr Cancer 31(2):101–105. doi:10.1080/01635589809514687
McMillan DC, Watson WS, O’Gorman P, Preston T, Scott HR, McArdle CS (2001) Albumin concentrations are primarily determined by the body cell mass and the systemic inflammatory response in cancer patients with weight loss. Nutr Cancer 39(2):210–213. doi:10.1207/S15327914nc392_8
McMillan DC, Crozier JE, Canna K, Angerson WJ, McArdle CS (2007) Evaluation of an inflammation-based prognostic score (GPS) in patients undergoing resection for colon and rectal cancer. Int J Colorectal Dis 22(8):881–886. doi:10.1007/s00384-006-0259-6
Meek CL, Wallace AM, Forrest LM, McMillan DC (2010) The relationship between the insulin-like growth factor-1 axis, weight loss, an inflammation-based score and survival in patients with inoperable non-small cell lung cancer. Clin Nutr 29(2):206–209. doi:10.1016/j.clnu.2009.08.013
Miyazaki T, Yamasaki N, Tsuchiya T, Matsumoto K, Kunizaki M, Taniguchi D, Nagayasu T (2015) Inflammation-based scoring is a useful prognostic predictor of pulmonary resection for elderly patients with clinical stage I non-small-cell lung cancer. Eur J Cardiothorac Surg 47(4):e140–e145. doi:10.1093/ejcts/ezu514
Ni XC, Yi Y, Fu YP, He HW, Cai XY, Wang JX, Zhou J, Cheng YF, Jin JJ, Fan J, Qiu SJ (2015) Prognostic value of the Modified Glasgow Prognostic Score in patients undergoing radical surgery for hepatocellular carcinoma. Medicine (Baltimore) 94(36):e1486. doi:10.1097/MD.0000000000001486
Pinato DJ, Shiner RJ, Seckl MJ, Stebbing J, Sharma R, Mauri FA (2014) Prognostic performance of inflammation-based prognostic indices in primary operable non-small cell lung cancer. Br J Cancer 110(8):1930–1935. doi:10.1038/bjc.2014.145
Proctor MJ, Morrison DS, Talwar D, Balmer SM, Fletcher CD, O’Reilly DSJ, Foulis AK, Horgan PG, McMillan DC (2011) A comparison of inflammation-based prognostic scores in patients with cancer. A Glasgow Inflammation Outcome Study. Eur J Cancer 47(17):2633–2641. doi:10.1016/j.ejca.2011.03.028
Rivadeneira DE, Grobmyer SR, Naama HA, Mackrell PJ, Mestre JR, Stapleton PP, Daly JM (2001) Malnutrition-induced macrophage apoptosis. Surgery 129(5):617–625. doi:10.1067/msy.2001.112963
Roxburgh CS, McMillan DC (2010) Role of systemic inflammatory response in predicting survival in patients with primary operable cancer. Future Oncol 6(1):149–163. doi:10.2217/fon.09.136
Tolia M, Tsoukalas N, Kyrgias G, Mosa E, Maras A, Kokakis I, Liakouli Z, Kouvaris JR, Liaskonis K, Charalampakis N, Pistevou-Gombaki K, Kelekis N, Kouloulias V (2015) Prognostic significance of serum inflammatory response markers in newly diagnosed non-small cell lung cancer before chemoirradiation. Biomed Res Int 2015:485732. doi:10.1155/2015/485732
Tomita M, Ayabe T, Chosa E, Nakamura K (2014) Prognostic significance of pre- and postoperative glasgow prognostic score for patients with non-small cell lung cancer. Anticancer Res 34(6):3137–3140
Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A (2015) Global cancer statistics, 2012. CA Cancer J Clin 65(2):87–108. doi:10.3322/caac.21262
Wicker N, Carles A, Mills IG, Wolf M, Veerakumarasivam A, Edgren H, Boileau F, Wasylyk B, Schalken JA, Neal DE, Kallioniemi O, Poch O (2007) A new look towards BAC-based array CGH through a comprehensive comparison with oligo-based array CGH. BMC Genom 8:84. doi:10.1186/1471-2164-8-84
Acknowledgments
The authors thank the staffs of the database and death registration system for their efforts in data collection and preprocessing. This research was supported by National Natural Science Foundation of China (Grant 81273187), National Science and Technology Major Project of the People’s Republic of China (Major Grant 2012ZX09303-013-014) and Key Lab of Health Technology Assessment, Ministry of Health of the People’s Republic of China.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Ethics approval
For this type of study, formal consent is not required. This article does not contain any studies with animals performed by any of the authors.
Additional information
Heng Fan and Zhi-Hui Xie have contributed equally to this work.
Rights and permissions
About this article
Cite this article
Fan, H., Shao, ZY., Xiao, YY. et al. Comparison of the Glasgow Prognostic Score (GPS) and the modified Glasgow Prognostic Score (mGPS) in evaluating the prognosis of patients with operable and inoperable non-small cell lung cancer. J Cancer Res Clin Oncol 142, 1285–1297 (2016). https://doi.org/10.1007/s00432-015-2113-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00432-015-2113-0